RAD101 Wins FDA Phase 3 Alignment: FASN-Targeted PET Scan Aims to End Brain MRI Ambiguity

0 points · first seen 1h ago · 1 outlet · 0 comments

RAD101 PET scan brain metastases diagnosis reached a pivotal milestone as Radiopharm Theranostics secured FDA alignment on a single 280-patient Phase 3 trial. The FASN-targeting fluorine-18 tracer distinguishes recurrent tumor from radiation necrosis after stereotactic radiosurgery - a dilemma no approved imaging agent currently solves. First patient dosing targets 2027. — Tech Times

save

· share to X · Bluesky · copy link